The ongoing goals of CORE A will be: 1) to provide generalized administrative support, 2) to insure efficient and appropriate usage of core services by the individual projects, 3) to coordinate and organize monthly research meetings of the program investigators, 4) to provide mechanisms of conflict resolution and potential rebudgeting issues, 5) to provide constructive review of the research through Internal and External advisory committees, 6) to provide budgetary services, such as tracking the expenditures of the program and providing monthly reports to the investigators, 7) to provide an objective quality assurance program that will monitor the clinical trials, and 8) to provide assistance and coordination with regulatory agencies within the Penn campus and with the FDA and R.A.C. The administrative functions (Goals 1-5) will be accomplished using a structure in which the Core Leader, Dr. Albelda, is advised by an Executive Committee of Project and Core Leaders with input from Internal and External Advisory Committees. He will be assisted by an administrative assistant, Ms. Pelzer. The budgetary goal (Goal 6) will be performed by Ms. Lavinia Pritchett. She will be responsible for facilitating communication and will have budgetary responsibility with oversight from Dr. Albelda. To provide an objective quality assurance program that will monitor the clinical trials, and to provide assistance and coordination with regulatory agencies within the PENN campus and with the FDA and R.A.C. (Goals 7 and 8), the Core will continue to utilize Penn's Office of Human Research and a regulatory consultant, Mr. Phillip Cross.

Public Health Relevance

Malignant mesothelioma is currently considered incurable. New approaches are needed. This Core provides the administrative infrastructure to support the clinical and preclinical studies of the Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066726-16
Application #
8566677
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
16
Fiscal Year
2013
Total Cost
$118,627
Indirect Cost
$68,021
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Aggarwal, Charu; Haas, Andrew R; Metzger, Susan et al. (2018) Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Mol Ther 26:1198-1205
Moon, Edmund K; Wang, Liang-Chuan S; Bekdache, Kheng et al. (2018) Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7:e1395997
Klampatsa, Astero; Haas, Andrew R; Moon, Edmund K et al. (2017) Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) 9:
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN? Combined with Chemotherapy. Clin Cancer Res 22:3791-800
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Andy, Uduak U; Harvie, Heidi S; Smith, Ariana L et al. (2015) Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn 34:424-8

Showing the most recent 10 out of 85 publications